Cell:DNA损伤揭示抗癌新疗法

2015-09-06 佚名 生物谷

大自然中每一个有机体都会不惜代价保护自身的DNA,但细胞如何精确区分自身DNA的损伤还是入侵病毒外源DNA的损伤依然是个谜底,近日刊登在国际杂志Cell上的一篇研究论文中,来自索尔克研究所的研究人员通过研究揭示了细胞反应系统精确区分上述两种威胁的机制,相关研究或可帮助开发新型的癌症选择性病毒疗法,同样也可以帮助理解为何老化和某些疾病似乎总在为病毒感染敞开着大门。研究者Clodagh O'Shea教


大自然中每一个有机体都会不惜代价保护自身的DNA,但细胞如何精确区分自身DNA的损伤还是入侵病毒外源DNA的损伤依然是个谜底,近日刊登在国际杂志Cell上的一篇研究论文中,来自索尔克研究所的研究人员通过研究揭示了细胞反应系统精确区分上述两种威胁的机制,相关研究或可帮助开发新型的癌症选择性病毒疗法,同样也可以帮助理解为何老化和某些疾病似乎总在为病毒感染敞开着大门。

研究者Clodagh O'Shea教授说道,本文研究阐明了一种基本的机制,即机体如何区分细胞和病毒基因组的DNA断裂来诱发不同的保护宿主的免疫反应,该研究或可帮助解释为何特定的状况,比如老化、癌症化疗以及炎症使我们机体对病毒感染变得更加敏感。

许多因子都会引发DNA断裂,研究者在文章中阐明了名为MRN复合体的一系列蛋白如何检测DNA和病毒的破裂,并且通过组蛋白来放大这种效应;MRN复合体蛋白会开启一种多米诺骨牌效应,激活染色体周围的组蛋白,最终引发一种广泛的效应来帮助机体细胞修复DNA。

一般来讲,常见的DNA病毒进入宿主细胞核后会开启复制自身DNA的基因的表达,而宿主细胞则会检测到这种未授权的复制,同时MRN复合体就会在不诱发杀细胞的广泛反应的前体下选择性地中和病毒的DNA,MRN对病毒的反应会在局部停留并且会仅仅选择性地抑制病毒;如果入侵的病毒会引发类似强烈的反应,那么细胞将会频繁地暂停生长。

文章中,研究者开发了新型病毒,其可以在正常细胞中被破坏,但可以在癌细胞中进行特异性复制,并不像正常细胞,癌细胞几乎总是包含高水平的DNA损伤,在癌细胞中,MRN或许会针对DNA破裂做出反应,但工程化的病毒或许就可以逃脱监视。癌细胞总是存在较高的突变率,而且在早期阶段会存在基因组的不稳定性,因此我们可以想象一下构建一种病毒来破坏早期机体损伤以及作为预防措施是多么困难的事情。

原文出处:

Govind A. Shah, Clodagh C. O’Shea.et al.Viral and Cellular Genomes Activate Distinct DNA Damage Responses.Cell.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (36)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959456, encodeId=921419594563d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 07 21:56:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080801, encodeId=2f5e208080172, content=<a href='/topic/show?id=637d5552168' target=_blank style='color:#2F92EE;'>#抗癌新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55521, encryptionId=637d5552168, topicName=抗癌新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 02 06:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869201, encodeId=bb2118692013e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 17 10:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36705, encodeId=acfb36e0517, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36704, encodeId=677c36e0437, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36698, encodeId=90c13669887, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:00:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36696, encodeId=01e93669645, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36693, encodeId=85b8366930b, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36694, encodeId=0bd13669410, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36695, encodeId=0f0b3669521, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-11-07 智智灵药
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959456, encodeId=921419594563d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 07 21:56:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080801, encodeId=2f5e208080172, content=<a href='/topic/show?id=637d5552168' target=_blank style='color:#2F92EE;'>#抗癌新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55521, encryptionId=637d5552168, topicName=抗癌新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 02 06:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869201, encodeId=bb2118692013e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 17 10:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36705, encodeId=acfb36e0517, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36704, encodeId=677c36e0437, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36698, encodeId=90c13669887, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:00:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36696, encodeId=01e93669645, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36693, encodeId=85b8366930b, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36694, encodeId=0bd13669410, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36695, encodeId=0f0b3669521, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1959456, encodeId=921419594563d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 07 21:56:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080801, encodeId=2f5e208080172, content=<a href='/topic/show?id=637d5552168' target=_blank style='color:#2F92EE;'>#抗癌新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55521, encryptionId=637d5552168, topicName=抗癌新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 02 06:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869201, encodeId=bb2118692013e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 17 10:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36705, encodeId=acfb36e0517, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36704, encodeId=677c36e0437, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36698, encodeId=90c13669887, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:00:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36696, encodeId=01e93669645, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36693, encodeId=85b8366930b, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36694, encodeId=0bd13669410, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36695, encodeId=0f0b3669521, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959456, encodeId=921419594563d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 07 21:56:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080801, encodeId=2f5e208080172, content=<a href='/topic/show?id=637d5552168' target=_blank style='color:#2F92EE;'>#抗癌新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55521, encryptionId=637d5552168, topicName=抗癌新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 02 06:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869201, encodeId=bb2118692013e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 17 10:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36705, encodeId=acfb36e0517, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36704, encodeId=677c36e0437, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36698, encodeId=90c13669887, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:00:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36696, encodeId=01e93669645, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36693, encodeId=85b8366930b, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36694, encodeId=0bd13669410, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36695, encodeId=0f0b3669521, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1959456, encodeId=921419594563d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 07 21:56:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080801, encodeId=2f5e208080172, content=<a href='/topic/show?id=637d5552168' target=_blank style='color:#2F92EE;'>#抗癌新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55521, encryptionId=637d5552168, topicName=抗癌新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 02 06:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869201, encodeId=bb2118692013e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 17 10:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36705, encodeId=acfb36e0517, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36704, encodeId=677c36e0437, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36698, encodeId=90c13669887, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:00:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36696, encodeId=01e93669645, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36693, encodeId=85b8366930b, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36694, encodeId=0bd13669410, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36695, encodeId=0f0b3669521, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1959456, encodeId=921419594563d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 07 21:56:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080801, encodeId=2f5e208080172, content=<a href='/topic/show?id=637d5552168' target=_blank style='color:#2F92EE;'>#抗癌新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55521, encryptionId=637d5552168, topicName=抗癌新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 02 06:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869201, encodeId=bb2118692013e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 17 10:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36705, encodeId=acfb36e0517, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36704, encodeId=677c36e0437, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36698, encodeId=90c13669887, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:00:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36696, encodeId=01e93669645, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36693, encodeId=85b8366930b, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36694, encodeId=0bd13669410, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36695, encodeId=0f0b3669521, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1959456, encodeId=921419594563d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 07 21:56:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080801, encodeId=2f5e208080172, content=<a href='/topic/show?id=637d5552168' target=_blank style='color:#2F92EE;'>#抗癌新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55521, encryptionId=637d5552168, topicName=抗癌新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 02 06:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869201, encodeId=bb2118692013e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 17 10:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36705, encodeId=acfb36e0517, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36704, encodeId=677c36e0437, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36698, encodeId=90c13669887, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:00:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36696, encodeId=01e93669645, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36693, encodeId=85b8366930b, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36694, encodeId=0bd13669410, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36695, encodeId=0f0b3669521, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1959456, encodeId=921419594563d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 07 21:56:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080801, encodeId=2f5e208080172, content=<a href='/topic/show?id=637d5552168' target=_blank style='color:#2F92EE;'>#抗癌新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55521, encryptionId=637d5552168, topicName=抗癌新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 02 06:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869201, encodeId=bb2118692013e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 17 10:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36705, encodeId=acfb36e0517, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36704, encodeId=677c36e0437, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36698, encodeId=90c13669887, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:00:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36696, encodeId=01e93669645, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36693, encodeId=85b8366930b, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36694, encodeId=0bd13669410, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36695, encodeId=0f0b3669521, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1959456, encodeId=921419594563d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 07 21:56:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080801, encodeId=2f5e208080172, content=<a href='/topic/show?id=637d5552168' target=_blank style='color:#2F92EE;'>#抗癌新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55521, encryptionId=637d5552168, topicName=抗癌新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 02 06:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869201, encodeId=bb2118692013e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 17 10:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36705, encodeId=acfb36e0517, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36704, encodeId=677c36e0437, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36698, encodeId=90c13669887, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:00:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36696, encodeId=01e93669645, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36693, encodeId=85b8366930b, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36694, encodeId=0bd13669410, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36695, encodeId=0f0b3669521, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1959456, encodeId=921419594563d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Nov 07 21:56:00 CST 2015, time=2015-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080801, encodeId=2f5e208080172, content=<a href='/topic/show?id=637d5552168' target=_blank style='color:#2F92EE;'>#抗癌新疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55521, encryptionId=637d5552168, topicName=抗癌新疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Aug 02 06:56:00 CST 2016, time=2016-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869201, encodeId=bb2118692013e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Sep 17 10:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36705, encodeId=acfb36e0517, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36704, encodeId=677c36e0437, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:22:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36698, encodeId=90c13669887, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 22:00:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36696, encodeId=01e93669645, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36693, encodeId=85b8366930b, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36694, encodeId=0bd13669410, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36695, encodeId=0f0b3669521, content=期待进一步的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e73d1605484, createdName=he408015781, createdTime=Thu Sep 10 21:59:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2015-09-10 he408015781

    期待进一步的研究

    0

相关资讯

Nat Commun:DNA损伤促衰老体内新证据

近日,国际学术期刊nature communication在线发表了美国科学家的一项最新研究进展,他们利用腺病毒系统在小鼠肝脏细胞内制造DNA双链断裂(DSB),在体内证明了DNA损伤会导致肝脏组织衰老,弥补了DNA损伤与组织器官衰老之间的体内证据,对于DNA损伤与衰老研究具有一定意义。   DNA双链断裂是DNA损伤众多类型中的一种,在几乎所有生物中都会发生,这一过程可以受到多种条

JBC:HD的发病及进程机制

来自中国科学院、北京大学的研究人员在新研究中揭示了线粒体钙信号失调、氧化应激与亨廷顿氏舞蹈病(HD)基因组DNA损伤之间的因果关系,这一发现对于了解HD的发病及进程机制,以及开发出有效的治疗策略具有重要意义。相关研究发表在《生物化学杂志》(JBC)上。 领导这一研究的是中科院动物研究所的唐铁山(Tie-Shan Tang)研究员。主要研究方向为神经细胞在生理和病理状态下钙信号的功能调控。近年来所

Cell:改动化疗药物顺序 或增强抗癌效果

       来自麻省理工David H. Koch癌症研究所,哈佛大学的研究人员发表了一篇文章,指出换个顺序使用抗癌药物,能重排细胞凋亡信号网络,从而增强细胞死亡。相关成果公布在Cell杂志上,并被作为头条内容推荐。        领导这一研究的是麻省理工David H. Koch 癌症研究所Michael B

Nat Cell Biol:促进乳腺癌细胞对放射疗法产生耐受的特殊蛋白ZEB1

近日,来自美国德州大学MD安德森癌症中心的研究人员通过研究发现,一种名为ZEB1(锌指E盒结合同源框蛋白)的蛋白质可以促进乳腺癌对放射疗法产生耐受性,研究者Li Ma博士表示,蛋白质ZEB1实际上可以帮助乳腺肿瘤细胞修复因辐射疗法带来的DNA损伤,而实现这一修复的机制或许是通过DNA损伤反应路径,相关研究刊登于国际杂志Nature Cell Biology上。 放射疗法可以通过诱导DNA破

Cell Reports:IFN-beta:早衰恶魔or抗肿瘤先锋?

长久以来,我们认为机体的衰老与DNA的损伤存在紧密的联系。老年人体内会出现大量的DNA突变事件,同时很多老龄化的症状开始显现。根据小鼠模型,老年小鼠的DNA损伤能够引起基因组的不稳定,影响干细胞的再生能力,从而导致组织的老化与异常。 虽然DNA损伤与细胞老化的联系长久以来深入人心,但其中的分子机制并不清楚,尽管之前有很多研究集中在DNA损伤事件发生后引起的旁分泌效应(paracrine acti